Project Grant R44AA033838
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $500K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded the Seattle Institute for Biomedical and Clinical Research $474,762 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate how blast-induced traumatic brain injury and chronic alcohol use interact to accelerate neurodegeneration and Alzheimer's disease and related dementia in preclinical rodent models. The research examines the glymphatic system—the brain's waste clearance mechanism—as a potential...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Ohio State University $474,223 on May 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to elucidate brain region- and cell-specific mechanisms of alcohol-induced developmental neurotoxicity and develop precision interventions targeting neuroprotection. The research addresses fetal alcohol spectrum disorder (FASD), which contributes significantly to intellectual disabilities with a prevalence rate of 1-5% in the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded the University of New Mexico Health Sciences Center $160,744 on March 9, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate electrophysiological mechanisms of prenatal alcohol exposure (PAE) effects on cognitive control. The project combines translational touchscreen testing and in vivo electrophysiology to determine how PAE impairs executive function domains in mouse models. The research hypothesizes that...
- The National Institute on Alcohol Abuse and Alcoholism awarded Weill Medical College of Cornell University $591,468 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct longitudinal neuroimaging analysis identifying neural risk factors for drinking onset in young adulthood. The recipient will apply machine learning analysis to nine years of longitudinal neuroimaging, behavioral, and neuropsychological data from 466 adolescents (baseline ages 12–18 years) enrolled in...
- The National Institute on Alcohol Abuse and Alcoholism awarded Creare LLC $314,357 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a wearable sensor system for continuous monitoring of alcohol withdrawal syndrome. The project delivers a real-time bracelet-based device integrating tremor detection, heart rate variability, sleep tracking, and sweat ethanol sensing with a machine learning algorithm that synthesizes multiple physiological inputs into a continuous...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of The University of Pennsylvania $727,664 under the Alcohol Research Programs (CFDA 93.273) Project Grant on May 1, 2026. The award funds multi-omics spatial analysis of single mouse brain neurons and astrocytes in response to ethanol challenge to advance understanding of alcohol use disorder. The work examines how chronic ethanol exposure alters the open-chromatin landscape and cytoplasmic transcriptome of neurons,...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Medical College of Wisconsin, Inc., $248,959 on September 12, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct a five-year longitudinal study examining reciprocal associations between brain function and alcohol use trajectories in adolescents and young adults. The recipient will assess prospective long-term associations between reward processing, cognitive control, and alcohol use patterns using two large...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...
- The National Institute on Alcohol Abuse and Alcoholism, part of the Department of Health and Human Services National Institutes of Health, awarded Mayo Clinic $404,352 on September 15, 2025, under the Alcohol Research Programs (CFDA 93.273) to develop machine learning and spatial transcriptomics tools for diagnosis and prognosis of alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and mixed-etiology metabolic syndrome-associated alcoholic...